Immuneering rises as quarterly loss comes in below estimates
06/03/2026 13:19
** Shares of therapy developer Immuneering IMRX.O rise 2.6% to $5.01 premarket ** Co reports Q4 adj. loss of 18 cents/shr vs analysts’ average estimate of 31 cents/shr – data compiled by LSEG ** Co says cash runway expected to fund operations into 2029 ** IMRX says expanded pancreatic cancer cohort data on track for 1H 2026 ** Dosing in mid‑stage trial of cancer drugs atebimetinib and Libtayo in lung cancer expected in 2H 2026, per co ** Shares up ~199% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))
Recent news on Immuneering
See all newsImmuneering expects cash runway to fund operations into 2029
Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend
U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences